Published in AIDS Weekly, May 17th, 1999
A Dutch/Swedish/U.S. research team compared T-helper immune responses in groups of rhesus macaque monkeys given one of three different envelope-based HIV vaccines. The vaccines used the HIV-1SF2 gp120 envelope glycoprotein expressed in vivo via DNA immunization (gene-gun administered); delivered as a subunit protein with MF59 adjuvant; or incorporated into ISCOMs.
"The best immune response to the gp120SF2 antigen was obtained by incorporating this antigen into ISCOMs," reported Ernst. J. Verschoor of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (1999-05-17)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.